International Comparison of Health Systems May 28, 2024 Page This Health Policy 101 chapter explores the performance of the U.S. health system on a number of cost, outcomes, and quality measures by comparing it with those in similarly large and wealthy OECD nations. It highlights that despite significant spending, Americans have shorter life expectancies and encounter more barriers to health care, influenced by both the health system’s structure and broader socioeconomic factors.
Donor Government Funding for Global Family Planning Declines to Lowest Level Since 2016 April 24, 2024 News Release A new KFF analysis finds donor government funding for family planning efforts in low- and middle-income countries totaled US$1.35 billion in 2022, a decline of 9% (US$129 million) compared to 2021 ($1.48 billion). This figure marks the lowest level of funding since 2016 ($1.31 billion). While some of the decline…
Donor Government Funding for Family Planning in 2022 April 24, 2024 Report This report provides an analysis of donor government funding to address family planning in low- and middle-income countries in 2022, which totaled US$1.35 billion and was a decline of 9% (US$129 million) compared to the 2021 amount (US$1.48 billion). While the decline was due to decreases in funding by most donor governments, a significant share can be attributed to exchange rate fluctuations resulting from the rise in value of the U.S. dollar against most currencies during 2022.
U.S. Federal Funding for HIV/AIDS: Trends Over Time March 26, 2024 Fact Sheet This fact sheet provides an updated overview of federal funding for HIV/AIDS, highlighting key domestic and global HIV/AIDS programs and comparisons over time.
Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss March 23, 2024 News Release A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted…
Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing March 22, 2024 Blog This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.
Domestic HIV Funding in the White House FY 2025 Budget Request March 12, 2024 Issue Brief This data note provides details on the FY25 request for domestic HIV programs and comparisons to the FY23 enacted level, where possible.
Halfway Through the Medicaid Unwinding, About 16 Million Enrollees Have Been Dropped January 30, 2024 News Release Ten months into the unwinding of the Medicaid continuous enrollment provision, states have reported renewal outcomes for half of all enrollees whose eligibility needs to be reviewed during the unwinding period, including 34% (32.1 million) who have had their coverage renewed, and 17% (16.2 million) who have been disenrolled, according…
Medicaid: What to Watch in 2024 January 30, 2024 Issue Brief As the start of 2024, many issues are at play that will affect Medicaid coverage, financing, and access. This issue brief provides context for these Medicaid issues and highlights key issues to watch in the year ahead.
Medicaid and State Financing: What to Watch in Upcoming State Budget Debates January 22, 2024 Issue Brief State legislatures are currently gathering to develop new budgets for state fiscal year (FY) 2025. Heading into this budget cycle, state fiscal conditions are shifting, with state revenues starting to decline following steep revenue growth during the pandemic. This issue brief examines trends in state fiscal conditions and discusses how state budgets and macroeconomic conditions may affect individuals and state Medicaid programs.